Summary In vivo '9F-NMR spectroscopy has been used to study the pharmacokinetics of the experimental antifolate drug CB3988 (C2-desamino-C2-methyl-N'0-propargyl-2'trifluoromethyl-5,8-dideazafolic acid) in mice and rats. NMR results have been compared to those obtained by HPLC and the effect of the inclusion of the CF3 group evaluated by comparing the pharmacokinetics of CB3988 and ICI 198583 (C2-desamino-C2-methyl-N'°-propargyl-5,8-dideazafolic acid) in rats. In mice, following the administration of CB3988 (500 mg kg-' i.v.), drug could be detected in both the upper and the lower abdomen. NMR signal from the upper abdomen reached maximum intensity 10-40 min after administration, declining thereafter with a half life of 28 min. Signal detected in the lower abdomen reached maximum intensity 60-90 min after treatment. HPLC analyses indicated that CB3988 was present at appreciable concentrations (about 20-30 mg ml-') in both bile and urine which is consistent with the signal from the upper and lower abdomen being derived from the gall bladder and urinary bladder, respectively. Studies in rats also indicated that CB3988 (100 mg kg-' i.v.) rapidly entered and was cleared from the upper abdomen. Comparison of data from rats with intact and cannulated bile ducts suggested that '9F-NMR could detect CB3988 undergoing enterohepatic circulation. Furthermore, comparison of the plasma half life of CB3988 with the half life for the decline of the NMR signal from the upper abdomen suggested that NMR measurements may reflect the plasma clearance of CB3988. When the pharmacokinetics of CB3988 and ICI 198583 were compared the only significant difference was in the alpha phase half life which was 2-fold faster for CB3988. These data demonstrate that CB3988 is cleared rapidly by both biliary and urinary excretion. This is in contrast to N'°-propargyl-5,8-dideazafolic acid, where delayed excretion is associated with hepatic and renal toxicities. The ability to study CB3988 pharmacokinetics non-invasively by '9F-NMR spectroscopy confirms the utility of the technique and, since '9F-NMR can be applied directly to clinical investigations, it may be possible to obtain similar information in humans.
It is now accepted that pharmacokinetics are an important determinant of both the activity and toxicity of anticancer drugs (Newell, 1989) . This acceptance has led to the inclusion of pharmacokinetic studies in both the preclinical and early clinical evaluation of the majority of novel antitumour agents with two broad aims in mind. Firstly, the studies may be of direct clinical relevance in determining dose escalation during phase I studies (Collins et al., 1986; EORTC PAM Group, 1987) and secondly the information gained may be of value in interpreting both the toxicity and activity of the compound. This latter information can in turn be used to develop either new drugs or drug schedules which maximise the therapeutic potential of the agent.
In order to conduct pharmacokinetic studies it is necessary to have a method which can accurately and selectively measure levels of the drug and its metabolites in biological fluids and tissues. Ideally the method should allow studies on drug levels in tumour deposits and in sensitive normal tissues since these are more likely to correlate with activity and toxicity than are levels in plasma or urine. In the preclinical setting such measurements are usually performed using radiochemicals and either autoradiographic or quantitative tissue distribution studies (Siddik & Newell, 1988 Stevens et al. (1984) were the first authors to demonstrate the utility of '9F-NMR as a method of non-invasively investigating the pharmacokinetics of a drug in vivo. These authors were able to measure drug in both the liver and tumours of mice following the administration of 5-fluorouracil (5FU) and were also able to detect metabolites of 5FU in both tissues. These studies have subsequently been extended to clinical investigations with 5FU (Wolf et al., 1987) and to work with other fluorinated drugs, most notably the inhalational anesthetics (Wrywicz et al., 1987; Selinsky et al., 1987 Selinsky et al., , 1988a .
In the present study the experimental antifolate C2-desamino-C2-methyl-N'0-propargyl-2'-trifluoromethyl-5,8-dideazafolic acid (CB3988, Figure la ) has been studied. CB3988 is the 2'trifluoromethyl derivative of C2-desamino-C2-methyl-N'°-propargyl-5,8-dideazafolic acid (ICI 198583, CB3819, Figure lb) which is itself an analogue of N'°-propargyl-5,8-dideazafolic acid (CB3717, Figure lc) . Although CB3717 displayed clinical activity it was withdrawn from use because of a number of side effects which included renal and hepatic toxicities (Calvert et al., 1986) . In experimental systems ICI 198583 is devoid of acute liver and kidney toxicity and is, surprisingly, markedly more potent than CB3717 in cytotoxicity studies (Hughes et al., 1988; Jackman et al., 1988) . The lack of toxicity seen with ICI 198583 is probably a reflection of its greatly enhanced aqueous solubility compared to CB3717 which is due to the lack of the 2-NH2 group in ICI 198583. In the case of CB3717, the presence of two hydrogen bond donors (N3H and 2-NH2) and two hydrogen bond acceptors (4-0 and N') allows strong intermolecular interactions and hence poor solubility. These interactions are reduced in the case of ICI 198583 which has a 2-methyl group instead of the 2-amino. With CB3717 there is a clear relationship between the pharmacokinetics of the drug and its toxicities. Thus in both mice and patients the drug is nephrotoxic and this is associated with its accumulation and retention in the kidney (Alison et al., 1985; Newell et al., 1986) . In mice the drug is Br. J. Cancer (1990), 62, 766-772 Cheshire. All other chemicals were of analytical grade where available and obtained from standard suppliers.
Synthesis of CB3988
The synthesis of CB3988 (Hughes, 1986; Marsham et al., 1990) was achieved as outlined in Figure 2 . Diazotization of the nitro aniline (1) and subsequent displacement of the diazo group by cyanide anion give the nitrile (2). Hydrolysis of the nitrile to carboxylate (4) was problematic, but was eventually achieved in two steps via the amide (3). Diethyl glutamate was condensed efficiently with the carboxylate acid chloride to give the nitro glutamate (5), which was then hydrogenated and the resulting amine (6) propargylated to give (7). Propargylamine (7) was coupled to bromomethyl quinazoline (8) and the coupled diester (9) hydrolysed to give CB3988 in good overall yield.
In vivo '9F-NMR spectroscopy Studies in mice '9F-NMR spectra were obtained using an Oxford Research Systems TMR-32 spectrometer with a 1.9T horizontal bore magnet. Mice were anaesthetised with 60 mg kg-' pentobarbitone intraperitoneally (i.p.) and when anaesthetised the urethra was ligated externally to prevent urination. The tail of the animal was warmed (42°C) and CB3988
given intravenously (i.v.) into a tail vein at 500 mg kg-' (50mg ml-' in 0.15 M NaHCO3, final pH adjusted to 9-9.5 with NaOH). Mice were then placed on a flask pumped with warm water so as to maintain the body temperature of the mouse at 36-38°C. The mouse and flask were then placed in the bore of the magnet and a 14 mm diameter two-turn (c) CB 3717 hepatotoxic and this is also associated with CB3717 retention in the liver (Newell et al., 1986) . In contrast, in mice, the non-toxic ICI 198583 is not retained in either the liver or the kidney . The aim of the present study was to confirm the rapid clearance of ICI 198583 from the liver and kidney by using '9F-NMR spectroscopy and in so doing to evaluate the potential NMR as a non-invasive method for pharmacokinetic monitoring. To achieve this aim the 2'triflouromethyl derivative of ICI 198583 was synthesised and the clearance of the drug from the liver and the appearance of the drug in the urinary bladder determined in mice. In addition, a study was performed in both normal and bile duct cannulated rats to determine the contribution of enterohepatic circulation to the NMR signal derived from the upper abdomen of the rat. The results obtained in mice by NMR were compared to those obtained using high performance liquid chromatography (HPLC) and in the rat the results obtained with CB3988 were compared to those gained with ICI 198583 to exclude the possibility that the present of the 2'trifluoromethyl was markedly influencing the pharmacokinetics of the drug. Certain aspects of this study have been reported previously in abstract form (Maxwell et al., 1990) CB3988 was administered to pentobarbitoneanaesthetised mice as described above. Thirty and 60min after administration the mice were killed and the liver, small intestine, large intestine, kidneys, lung, heart, spleen and stomach removed. and over this range the recovery of CB3988 was complete (98 ± 4%, mean ± s.d., n = 21) and linear (r = 1.000) with intra and interassay coefficients of variation of < 10%.
Comparison of the pharmacokinetics of CB3988 and ICI 198583 in rats To determine any possible effect of the 2'trifluoromethyl group in CB3988 the pharmacokinetics of ICI 198583 were also determined in bile duct cannulated rats using the method described above. The only exception was that the body temperature of the rats was maintained by using external heating lamps. ICI 198583 levels were determined in an identical manner to that described for CB3988. Recovery of ICI 198583 from rat plasma was also complete (101.9 + 7.4%) and linear (r = 1.000) and under the HPLC conditions used ICI 198583 (retention volume 11.6 ml) was resolved from CB3988 (retention volume 16.8 ml) with the 313/280 nm absorbence ratios also being different (ICI 198583 = 0.94 + 0.08, CB3988 = 0.43 ± 0.01).
Pharmacokinetic analysis of data NMR signals The NMR peak heights for each animal were measured and then each peak expressed as a fraction of the most intense peak observed for the individual animal. The relative peak heights will be proportional to peak areas and hence to the concentration of free drug in each animal provided that no changes in line width occur during the course of the experiment. No such changes were apparent. Peak intensity vs time plots were then drawn and half-life values calculated for the decline in peak intensity during the exponential phase. Half-lives were calculated by non-linear least squares regression analysis (Jennrich & Sampson, 1968) using a weighting function of l/(y + 9)2.
Plasma levels of CB3988 and ICI 198583 in rats A biexponential equation was fitted to plasma CB3988 and ICI 198583 levels following their administration to rats. As above, nonlinear least squares regression analysis employing a weighting function of l/(y + 9)2 was used. From the fitted equation the alpha and beta phase half-lives, clearance and volume of distribution at steady state were calculated using standard equations (Houston, 1985) .
Results
'9F-NMR spectroscopy of CB3988 in mice Figure 3 shows examples of the spectra obtained from the upper abdomen of mice 40, 80 and 120 min after the i.v. administration of 500 mg kg-' CB3988. These data show that the NMR signal was readily detectable at these time points; however, the signal was nearing the limit of detection at 120 min. No clear evidence of the presence of additional peaks in the NMR spectrum was seen at any time point and hence metabolism of CB3988 at a site close enough to the 2' position to substantially alter the chemical shift of the trifluoromethyl signal is not indicated. Figure 4 displays the time course for the appearance and disappearance of the signal in the upper abdomen of mice and shows that the signal tended to increase over the first 10-40min, decaying therafter. The half-lives for the decline in the NMR signal for the three mice whose data are given in Figure 4 were 23 ± 4, In order to allow the NMR signals arising from the upper and lower abdomen of the mice to be ascribed to particular organs of the mouse a conventional quantitative tissue distribution study was performed 30 and 60 min after administration. As shown in Table I , of the organs analysed only the gall bladder and urinary bladder contained drug at appreciable concentrations (about 20-30mgml'). Of the other organs studied only the liver and small intestines contained drug in excess of 1 mg g-' wet weight. On the basis of these data it seems probable that the signal arising from the upper abdomen is derived primarily from drug in the gall bladder whilst signal from the lower abdomen corresponds to drug in the urinary bladder. '9F-NMR spectroscopy of CB3988 in rats The time course for the appearance and decline of NMR signal from the upper abdomen of rats following the administration of 100 mg kg' CB3988 is shown in Figure 6 . Data for rats with intact and cannulated bile ducts are given and, as in the case of mice, all spectra contained only the peak associated with CB3988, no metabolites being detected. In both cannulated and bile duct-intact rats, NMR signal was detected within 2 min of the bolus dose of CB3988 with signal intensity reaching a maximum value by 10 min. Thereafter the signal declined rapidly, particularly in bile duct cannulated rats where the limit of detection was reached by 15-20 min and signal was not detected again during the remainder of the experiment (60 min). The half-lives for the decline in the NMR in the three bile duct cannulated rats were 6.5 ± 0.8, 6.9 ± 0.8 and 5.6 + 2.9 min, overall mean 6.5 ± 0.8 min. In the rats with intact bile ducts the NMR signal did not decline as rapidly as in the cannulated rats and did not drop below the limit of detection during the experiment (0-60 min). Indeed, in two of the rats, from 30 min onwards the NMR signal had stabilised. These data suggest that the signal detected in rats with intact bile ducts is due in part to drug re-entering the liver as part of the enterohepatic cycle. However, as shown in Figure 7 and Table II, there were no significant differences in the plasma levels or urinary excretion of CB3988 in rats with or without bile duct cannulae which probably reflects efficient uptake of CB3988 present in the portal system such that there is no passage of compound into the systemic circulation.
Comparison of the pharmacokinetics of CB3988 and ICI 198583 in rats To investigate the possibility that the 2'-trifluoromethyl group of CB3988 was a major determinant of the pharmacokinetics of the drug a comparison was made between CB3988 and its parent ICI 198583. The plasma levels of CB3988 and ICI 198583 are shown in Figure 7 and the pharmacokinetic parameters and urinary and bilary excretion data given in Table II . Inclusion of the 2'-trifluoromethyl group reduced the alpha phase half-live value (t test, P = 0.004) and this led to levels of CB3988 being lower than those of ICI 198583, however, this was the only pharmacokinetic parameter for which there was a significant difference between CB3988 and ICI 198583.
Discussion
The aim of the present study was to evaluate the utility of non-invasive '9F-NMR spectroscopy as a method of studying the pharmacokinetics of the antifolate CB3988 in mice and rats. This study is important both with regard to this particular class of compounds and because there is a general need to study non-invasive methods of pharmacokinetic monitoring in cancer chemotherapy. In both mice and rats NMR signal could be readily detected in the upper abdomen of the animal shortly after drug administration. Comparison of the NMR data with those of a conventional quantitative tissue distribution study performed using HPLC analysis demonstrated that the signal in the upper abdomen of mice was most probably derived from the gall bladder. Associated studies using whole body '9F-NMR imaging in mice following the administration of CB3988 confirm that the signal from the upper abdomen is derived from a discreet volume whose position is anatomically consistent with that of the gall bladder (Maxwell et al., 1990) . The other area examined in mice was the lower abdomen where signal was also readily detected. Again on the basis of HPLC analyses (Table I) and '9F-NMR imaging (Maxwell et al., 1990 ) the source of the signal would appear to be primarily the urinary bladder. The time course of the appearance of the drug in the bladder indicates that the urinary excretion of the drug occurs rapidly and is essentially complete within 1 h ( Figure 5 ). This is in marked contrast to the nephrotoxin CB3717 where there is delayed urinary excretion and drug still present in the kidney weeks after administration (Newell et al., 1986) . Thus NMR does appear to be capable of identifying rapid urinary elimination with this class of compound. In the light of clinical experience with CB3717 (Calvert et al., 1986; Alison et al., 1985) this information would be useful in the early clinical evaluation of CB3717 analogues.
In addition of urinary excretion, faecal elimination constitutes the other major route of excretion for CB3717 (Newell et al., 1986 ) and its analogues . Faecal elimination is preceded by biliary clearance with the majority of the dose present in the bile within I h in the case of both ICI 198583 and CB3988 (Table 11 ). This is also the case for CB3717 itself at non-hepatotoxic doses (Newell & Siddik, unpublished results) . Since biliary excretion is the major route of elimination, and the NMR signal from the upper abdomen of mice derives from the bile in the gall bladder, a relationship between the rate of decline in the plasma levels of CB3988 and the NMR signal might be anticipated. Although the plasma levels of CB3988 in mice were not determined as part of the present study, previous results with other C2-desamino quinazolines indicate that the plasma half-life is approximately 20 min . This value is consistent with that of 28 ± 6 min for the decline in the NMR signal reported herein. Thus for drugs which undergo extensive biliary elimination NMR studies of drug clearance from the liver may offer an indirect measure of plasma half-life. More generally, in those cases where drugs can be detected in organs of direct therapeutic or toxicological interest the results of NMR experiments may be more relevant than plasma analyses. For example, the relationship between drug levels in tumour tissue and activity should be better than that between plasma levels and activity.
Experiments were performed in rats to further investigate the relationship between CB3988 plasma half-life and the decline in NMR signal since it was technically possible to take blood samples, collect bile and perform spectroscopic experiments on the same animal. The experiments in bile duct cannulated rats, where enterohepatic circulation cannot occur, indicated that the alpha phase half-life for the clearance of CB3988 from plasma was 3.6 ± 0.3 min while the NMR signal from the upper abdomen decreased with a half-life of 6.5 ± 0.8 min. The similarity of these values again encourages the view that the signal from the liver can be used as an indirect measure of the plasma half-life of a drug, provided that the liver is the major organ for the clearance of the compound. When experiments were repeated in rats with an intact bile duct a more complex profile was obtained for the time course of NMR signal intensity from the upper abdomen ( Figure 6 ). The difference between these results and those in bile duct cannulated animals strongly suggests an element of enterohepatic circulation in the disposition of the drug. Enterohepatic circulation has been observed in rats with CB3717 (Newell & Siddik, unpublished results) and '9F-NMR SPECTROSCOPY OF A QUINAZOLINE ANTIFOLATE 771 methotrexate (Griffin & Said, 1987) , and hence is not unexpected.
The rapid decline in the NMR signal from the liver of both mice and rats following CB3988 administration is again in contrast to the data obtained in mice (Newell et al., 1986) and rats (Newell & Siddik, unpublished results) with CB3717. In both species reduced clearance of the drug from the liver was associated with hepatotoxicity. With C2-desamino analogues of CB3717 both retention of drug in the liver and hepatotoxicity are absent . However, these results were obtained using invasive techniques. The demonstration in the present study that it is possible to show rapid hepatic clearance non-invasively by NMR is again an encouraging result which would also be of value in the early clinical evaluation of CB3717 analogues.
The final point investigated in this study concerned the impart of the inclusion of the 2'-trifluoromethyl group on the pharmacokinetics of the antifolate molecule. In this respect the only significant effect of the 2'-trifluoromethyl group was to reduce the alpha phase half-life value with the result that plasma levels of CB3988 were lower than those of ICI 198583 (Figure 7) . No other major qualitative or quantitative alterations in the distribution of the molecule, its clearance or its routes of elimination were observed.
However, it should be noted that associated biochemical studies have shown that the presence of the 2'-trifluoromethyl group reduces both the inhibitory activity of the compound towards the target enzyme, thymidylate synthase (7-fold), and the cytotoxicity of the agent (14-fold) in comparison to ICI 198583 (A.L. Jackman, unpublished results). Thus the potential problems of including the trifluoromethyl group as a 'label' in candidate drugs should not be underestimated and the use of a single fluorine atom may be more appropriate, but the resultant loss in sensitivity might compromise the utility of the methodology.
With regard to the general application of '9F-NMR in pharmacokinetic studies a number of points need to be considered. The major limitation of NMR is that the technique has only limited sensitivity. Thus in the present study signal detected in the upper and lower abdomen of mice was ascribed to drug present in the bile and urine at concentrations of 20-30mgml1' (40-60mM) . The dynamic range in these studies was approximately 10-fold and hence that limit of detection would be in the region of 4 mM. This figure could be reduced by the use of longer aquisition periods; however, in so doing time resolution would be lost which may be critical in the case of drugs with short half-lives. In contrast, conventional methods involving radiochemical and/ or chromatographic analyses can provide information on drug levels in the low nM region. Thus, in the absence of marked improvements in sensitivity, in vivo '9F-NMR will only find application in those cases where relatively large doses of drug can be administered. This was possible in the case of CB3988 as C2-desamino quinazoline antifolates can be administered to mice at 500mgkg-' without producing any acute toxicity . Since a number of antitumour agents are relatively impotent compounds, with clinical doses in the 100 mg to I g range, cancer chemotherapy represents an ideal area in which to assess the applications and limitations of in vivo '9F-NMR.
Despite the limitations of sensitivity with regard to in vivo spectroscopy, it is already clear that ex vivo analytical '9F-NMR does have considerable potential as a method to study drug and metabolite levels using biological fluids and isolated tissues. A number of studies have already shown the utility of the method in the case of the fluoropyrimidine drugs (MaletMartino et al., 1984 (MaletMartino et al., , 1986 Keniry et al., 1986; Vialaneix et al., 1987; Hull et al., 1988) . The use of 'fluorine labels' in other anticancer drugs is clearly warranted and recent work with nitroimidazoles is a further example of this (Maxwell et al., 1989) . The studies with the fluoropyrimidines serve to highlight the major strength of NMR over radiochemical studies, namely, that the technique provides separate information on drug metabolites and the parent compound and not just on total drug derived material. This aspect of '9F-NMR was not apparent from the study reported in the present paper because quinazoline antifolates do not undergo extensive metabolism. Thus in the case of CB3717, the only extracellular metabolite which has been detected is the desglutamate compound which was found in the faeces and was shown to be a product of bacterial metabolism in the gastrointestinal tract (Newell et al., 1986) . Although polyglutamate metabolites of CB3717 have also been detected, both in vitro (Sikora et al., 1988) and in vivo (Manteufel-Cymborowska et al., 1986; Nair et al., 1986) , these compounds are thought to be rapidly catabolised once outside the cell. Within the cell polyglutamates are probably highly protein bound and would not have the freedom of motion required for a molecule to be detected by NMR. This requirement for molecules to be free to move in order to be detected by NMR spectroscopy may place an additional limitation on the detection of drugs in biological tissues since the line widths of NMR signals depends upon the rotational freedom of the nuclei involved. Thus the binding of a small molecule to a protein can result in line broadening to such an extent that some or all of the nuclei become 'NMR invisible'. Preliminary studies with CB3988 indicated that when the drug was added at 2 mM to a 50% (v/v) mouse liver homogenate the peak height signal to noise ratio was reduced 4-fold relative to an aqueous solution of the drug at the same concentration. Further experiments are required to define the extent to which this phenomenom will limit the application of in vivo NMR.
In conclusion, this study has demonstrated the utility of in vivo '9F-NMR spectroscopy as a method for studying the pharmacokinetics of a quinazoline antifolate drug in mice and rats. The results obtained by NMR indicate that CB3988 is cleared rapidly by both biliary and urinary elimination. These data are consistent with the lack of liver and kidney toxicity found with the C2-desamino CB3717 analogues.
Comparison of the NMR data with data obtained using conventional HPLC methodology indicates that the NMR signals detected in the upper and lower abdomen of mice are derived from the gall bladder and urinary bladder, respectively. Pharmacokinetic analyses in both mice and rats suggest that the rate of decline of the NMR signal derived from the upper abdomen may reflect the rate of drug clearance from the plasma and that in rats NMR can detect compound undergoing enterohepatic circulation. Comparison of the pharmacokinetics of CB3988 and ICI 198583 in rats indicated that the inclusion of the 2'trifluoromethyl group reduced the alpha phase half life, however, it did not markedly alter the rate or route of drug clearance. 
